$2.3 B

ENTA Mkt cap, 11-Jul-2018

$82.2 M

Enanta Pharmaceuticals Revenue Q2, 2018
Enanta Pharmaceuticals Net income (Q2, 2018)24.2 M
Enanta Pharmaceuticals EBIT (Q2, 2018)31.2 M
Enanta Pharmaceuticals Cash, 31-Mar-201866.9 M

Enanta Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

32.1 m47.7 m160.9 m88.3 m102.8 m

Revenue growth, %

49%237%(45%)

R&D expense

40.5 m57.5 m

General and administrative expense

17 m20.7 m

Operating expense total

57.4 m78.2 m

Depreciation and amortization

2.1 m

EBIT

9 m19 m124.1 m30.8 m24.6 m

EBIT margin, %

28%40%77%35%24%

Interest expense

31 k18 k8 k45 k40 k

Interest income

248 k467 k968 k1.7 m2.5 m

Pre tax profit

19.3 m125.5 m32.6 m26.9 m

Income tax expense

15.2 m(46.5 m)(10.9 m)(9.2 m)

Net Income

9.6 m34.4 m79 m21.7 m17.7 m

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018

Revenue

42.1 m77.5 m57.4 m11.6 m48.4 m13 m14 m10.4 m9 m82.2 m

R&D expense

4.6 m4.5 m5.4 m6.3 m9 m9.1 m10.8 m12.5 m13 m39.4 m

General and administrative expense

2.6 m2.8 m3.4 m3.6 m3.8 m4.4 m4.3 m4.9 m5.5 m11.5 m

Operating expense total

7.2 m7.3 m8.8 m9.9 m12.9 m13.6 m15.1 m17.5 m18.5 m50.9 m

EBIT

34.9 m70.2 m48.6 m1.7 m35.6 m(565 k)(1.1 m)(7 m)(9.5 m)31.2 m

EBIT margin, %

83%91%85%15%73%(4%)(8%)(68%)(106%)38%

Interest expense

5 k2 k2 k2 k12 k11 k11 k12 k8 k2 m

Interest income

106 k127 k229 k304 k356 k408 k474 k549 k572 k2 m

Pre tax profit

34.9 m2 m35.9 m(642 k)(6.5 m)(9 m)33.3 m

Income tax expense

15.1 m(28.5 m)(20 m)428 k(9.7 m)(1.6 m)(434 k)1.5 m3.6 m(9 m)

Net Income

39.5 m42 m70.8 m73.2 m26.2 m24.5 m23.5 m(5 m)(10.4 m)24.2 m

Enanta Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

8.9 m30.7 m21.7 m16.6 m65.7 m

Accounts Receivable

808 k1.7 m15.3 m12.8 m10.6 m

Inventories

1.6 m1.6 m8.3 m9.2 m3.5 m

Current Assets

104.7 m108 m170.6 m232.2 m237.8 m

PP&E

1.1 m1.8 m5.9 m8 m8 m

Total Assets

117 m155.4 m246 m281.3 m326.6 m

Accounts Payable

1.5 m1.9 m1.5 m3.4 m3.7 m

Short-term debt

Current Liabilities

4.5 m4.7 m6.7 m7.9 m21 m

Long-term debt

Total Liabilities

11.3 m25 m

Additional Paid-in Capital

217.7 m221.6 m230 m242.1 m256.2 m

Retained Earnings

(107.5 m)(73 m)6 m27.6 m45.4 m

Total Equity

110.5 m148.7 m236.2 m269.9 m301.7 m

Financial Leverage

1.1 x1 x1 x1 x1.1 x

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018

Cash

26.4 m34.1 m25.8 m19.8 m46.2 m56.4 m24.8 m20.6 m19.2 m66.9 m

Accounts Receivable

399 k76.6 m7.1 m11.7 m17.9 m13 m14 m10.4 m9 m44 m

Current Assets

111.7 m185.1 m177.8 m172.6 m209 m242.7 m241.8 m224.1 m190.6 m305.7 m

PP&E

1.6 m1.9 m2.3 m2.6 m7.9 m7.7 m7.5 m8.3 m8.5 m8.6 m

Total Assets

159.5 m215.4 m245.9 m237.8 m278.4 m281.6 m281.9 m278.4 m279 m354.7 m

Accounts Payable

1.3 m567 k2.3 m1.6 m2.8 m2.6 m2 m2 m4.1 m4.7 m

Current Liabilities

4.3 m19.9 m19.8 m7.3 m10.9 m12 m9.6 m6.4 m9.2 m17.1 m

Total Liabilities

21.3 m

Additional Paid-in Capital

220.7 m224.6 m226.3 m228 m232.1 m235.5 m239.3 m245.4 m248.7 m264.4 m

Retained Earnings

(68 m)(31 m)(2.3 m)168 k32.2 m30.5 m29.4 m22.7 m17.3 m69.6 m

Total Equity

153 m193.7 m224.2 m228.3 m264.3 m266.4 m269 m268.2 m266 m333.4 m

Financial Leverage

1 x1.1 x1.1 x1 x1.1 x1.1 x1 x1 x1 x1.1 x

Enanta Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

9.6 m34.4 m79 m21.7 m17.7 m

Depreciation and Amortization

221 k352 k639 k1.7 m2.1 m

Accounts Receivable

241 k(916 k)(14 m)2.4 m2.2 m

Inventories

(307 k)568 k(6.7 m)(964 k)3.5 m

Accounts Payable

115 k399 k(543 k)1.5 m633 k

Cash From Operating Activities

10.7 m20.2 m76.7 m35.8 m52.7 m

Purchases of PP&E

(606 k)(1 m)(2.3 m)(4.7 m)(2.5 m)

Cash From Investing Activities

(69.2 m)497 k(88.2 m)(43.7 m)(4.6 m)

Cash From Financing Activities

56.9 m1.2 m2.5 m2.7 m1 m

Interest Paid

Income Taxes Paid

148 k40.1 m12.6 m1.6 m

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018

Net Income

39.5 m42 m70.8 m73.2 m26.2 m24.5 m23.5 m(5 m)(10.4 m)24.2 m

Depreciation and Amortization

242 k129 k270 k435 k339 k772 k1.2 m493 k1 m1.2 m

Accounts Receivable

409 k(74.9 m)(5.4 m)(10 m)(2.6 m)2.3 m1.3 m2.4 m3.9 m(33.4 m)

Accounts Payable

(190 k)(1.3 m)488 k(332 k)149 k1.2 m677 k(1.3 m)688 k565 k

Cash From Operating Activities

25.1 m(5.6 m)93.3 m79 m30 m40 m37.9 m3.1 m143 k(3.2 m)

Purchases of PP&E

(543 k)(256 k)(356 k)(756 k)(2.2 m)(3.7 m)(4.3 m)(953 k)(1.5 m)(1.3 m)

Cash From Investing Activities

(8.7 m)7 m(100.5 m)(92.3 m)(5.6 m)(6.1 m)(37.5 m)865 k2.7 m4 m

Cash From Financing Activities

1.1 m2 m2.3 m2.4 m146 k676 k2.6 m31 k(180 k)411 k

Income Taxes Paid

66 k22.1 m39.6 m5.7 m5.7 m9.1 m1 m1 m9.9 m

Enanta Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information